Atropine

CHEMBL517712 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
289.4 g/mol
LogP
1.8
Phase
4

A muscarinic receptor antagonist derived from the belladonna plant that blocks the effects of acetylcholine on the parasympathetic nervous system, increasing heart rate, drying secretions, and relaxing smooth muscle. It is used in emergencies for bradycardia and to reverse certain poisonings.

Molekularmasse

289,4000 g/mol

LogP

1,80

TPSA

49,80 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Wirkmechanismus

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2

InChI

InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15+,16?

Molecular Formula

C17H23NO3

HBD / HBA

1 / 4

Rotierbare Bindungen

5

Schwere Atome

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A muscarinic receptor antagonist derived from the belladonna plant that blocks the effects of acetylcholine on the parasympathetic nervous system, increasing heart rate, drying secretions, and relaxing smooth muscle. It is used in emergencies for bradycardia and to reverse certain poisonings.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Atropine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL517712. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 174174. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.